Nanoscope Therapeutics Reports Three-Year Vision Gains from REMAIN Study of MCO-010 in Retinitis Pigmentosa

Dallas-based Nanoscope Therapeutics, a Texas biotechnology company developing optogenetic therapies for retinal diseases, announced durable three-year vision improvements from the REMAIN study of its MCO-010 therapy for retinitis pigmentosa. Patients maintained an average three-line gain in visual acuity with a favorable safety profile, supporting the ongoing rolling Biologics License Application with the FDA. If approved, MCO-010 could become the first FDA-approved optogenetic therapy and a one-time treatment option for patients with severe vision loss.